Stock listing

NASDAQ:CGON CG Oncology, Inc. Stock

Home listing (NASDAQ) of CG Oncology, Inc.

Follow CG Oncology, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CGON

$79.47 USD -0.53 (-0.7%)

Close on Nov 20, 2026

Past year +95.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$79.23 – $83.12 USDNov 20, 2026
Volume
1.67M sharesNov 20, 2026
Market cap
$7.10B USDAt the close on Nov 20, 2026 · price × 89.32M shares outstanding
52-week range
$37.01 – $93.95 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$87.07M USDMedian day 890,166 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
CG Oncology, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CGON · Home$79.47 USD-0.53 (-0.7%)1,673,971$80.32$83.12$79.23$80.00Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CGON · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$79.47-0.53-0.7%$80.32$83.12$79.231,673,971
$80.00+1.06+1.3%$79.07$82.08$77.351,792,746
$78.94-5.84-6.9%$82.51$83.97$73.003,160,874
$84.78+10.38+14.0%$92.00$93.95$78.279,881,332
$74.40+4.25+6.1%$71.19$76.06$68.133,238,544
$70.15-2.46-3.4%$72.21$72.96$67.431,277,579
$72.61-0.030.0%$73.21$75.19$72.49890,166
$72.64-2.10-2.8%$73.84$74.95$71.26821,216
$74.74-1.25-1.6%$77.19$77.99$72.411,511,579
$75.99+11.19+17.3%$66.49$80.00$66.463,661,704
$64.80-2.91-4.3%$67.34$67.34$64.16931,516
$67.71+3.65+5.7%$66.10$67.87$63.161,304,790
$64.06+2.10+3.4%$62.52$65.79$62.35724,745
$61.96-2.72-4.2%$64.18$64.68$61.011,279,526
$64.68+1.21+1.9%$63.02$65.55$60.63870,326
$63.47-0.49-0.8%$64.28$65.59$63.08782,614
$63.96+1.02+1.6%$62.53$64.12$62.30944,090
$62.94+1.38+2.2%$61.46$64.13$59.96709,340
$61.56-0.15-0.2%$61.76$62.80$61.06880,160
$61.71-0.83-1.3%$62.36$62.36$59.861,064,552
$62.54+0.30+0.5%$61.95$63.19$61.40579,519
$62.24+0.31+0.5%$62.43$63.57$61.27530,138
$61.93+1.97+3.3%$60.16$62.71$60.16766,680
$59.96+0.11+0.2%$60.44$61.25$59.221,215,168
$59.85-2.01-3.2%$61.86$62.00$59.371,079,700
$61.86+0.020.0%$62.70$63.24$60.961,186,400
$61.84-0.56-0.9%$62.48$63.44$61.271,100,400
$62.40-0.73-1.2%$61.92$63.85$61.521,188,600
$63.13-0.69-1.1%$63.43$64.15$62.68660,600
$63.82+0.56+0.9%$62.97$65.18$62.88516,500
$63.26+0.88+1.4%$61.65$63.71$61.11910,300
$62.38-1.26-2.0%$62.68$63.64$61.90621,800
$63.64-5.07-7.4%$69.17$69.17$63.19774,400
$68.71+1.33+2.0%$67.60$68.95$65.71788,400
$67.38-0.97-1.4%$69.35$69.73$66.611,541,100
$68.35-2.54-3.6%$70.38$71.27$68.32984,900
$70.89+0.37+0.5%$70.34$73.16$69.231,330,900
$70.52+0.91+1.3%$69.56$70.68$68.261,035,400
$69.61+2.46+3.7%$66.96$69.94$66.011,759,600
$67.15-1.61-2.3%$69.32$70.05$66.761,177,500
$68.76-4.60-6.3%$73.10$73.44$68.151,444,200
$73.36-4.38-5.6%$76.87$77.79$71.86830,900
$77.74-0.51-0.7%$78.31$80.63$76.251,641,900
$78.25+3.63+4.9%$75.74$78.47$74.221,114,900
$74.62-1.00-1.3%$75.87$75.87$72.821,779,200
$75.62+1.50+2.0%$75.00$76.50$74.43894,300
$74.12+1.57+2.2%$72.66$74.59$72.66795,600
$72.55-1.24-1.7%$74.13$74.13$72.481,037,300
$73.79+1.44+2.0%$72.30$74.67$71.78829,900
$72.35+0.35+0.5%$72.82$75.00$71.53759,800
$72.00+0.04+0.1%$70.91$72.58$70.00657,900
$71.96-1.44-2.0%$73.04$74.85$70.90707,900
$73.40-1.27-1.7%$73.23$74.60$72.25550,800
$74.67+0.34+0.5%$73.02$74.88$72.87282,500
$74.33-0.26-0.3%$74.94$75.02$73.69359,700
$74.59-1.27-1.7%$76.84$79.23$73.89663,900
$75.86+0.70+0.9%$74.74$76.24$74.20876,100
$75.16+0.82+1.1%$74.09$76.14$72.12840,700
$74.34-4.67-5.9%$78.15$78.16$73.93612,600
$79.01+0.59+0.8%$78.01$79.40$77.63328,900
$78.42-0.53-0.7%$78.29$78.94$76.87507,800
$78.95+0.72+0.9%$79.00$80.07$78.10736,169
$78.23-1.58-2.0%$79.44$79.89$77.511,162,618
$79.81+2.20+2.8%$78.69$79.89$77.38701,700
$77.61-3.07-3.8%$79.50$79.71$77.17668,000
Ticker
NASDAQ:CGON
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All CG Oncology, Inc. news

CG Oncology, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 60 in all · newest Nov 6, 2026 · oldest 2024
Decks
31 decks · latest Nov 16, 2026

Where CG Oncology, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CGON · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CGONBOATSUnited StatesUSD

Valuation

EV/sales 992× against a median of 13.5×: the highest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$6.12B USD
P/E
Loss
EV/sales
992×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
7.2×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
0.83

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
CG Oncology, Inc. · NASDAQ:CGONUS$7.10BUS$6.12Bn/a992×n/a7.2×n/a0.0×0.83
Summit Therapeutics Inc. · NASDAQ:SMMTUS$7.96BUS$7.33Bn/an/an/a14.1×n/a0.0×1.91
Protagonist Therapeutics, Inc. · NASDAQ:PTGXUS$7.92BUS$7.13B23.1×12.9×22.0×7.3×62.0%0.0×0.93
Alkermes plc · NASDAQ:ALKSUS$7.55BUS$8.31Bn/a4.7×57.3×4.0×−0.0%0.8×0.80
Cytokinetics, Incorporated · NASDAQ:CYTKUS$7.07BUS$6.36Bn/a56.2×n/an/a−686.6%n/a0.93
Axsome Therapeutics, Inc. · NASDAQ:AXSMUS$6.80BUS$6.68Bn/a7.7×n/a64.5×−18.2%1.8×0.69
Akeso, Inc. · HKEX:9926US$6.66BUS$6.04Bn/a13.5×n/a5.2×−36.4%0.6×n/a
Immunovant, Inc. · NASDAQ:IMVTUS$6.57BUS$5.85Bn/a825×n/a10.0×n/a0.0×1.46
Oruka Therapeutics, Inc. · NASDAQ:ORKAUS$6.50BUS$5.58Bn/an/an/a5.4×n/a0.0×1.30
ImmunityBio, Inc. · NASDAQ:IBRXUS$6.40BUS$6.10Bn/a33.4×n/an/a−607.8%n/a1.50
Kodiak Sciences Inc · NASDAQ:KODUS$6.35BUS$6.31Bn/an/an/a505×n/a3.7×1.58
Median of the othersUS$6.73BUS$6.34B23.1×13.5×39.6×8.7×−27.3%0.3×1.30

Forecasts

9 strong buy · 4 buy · 1 hold · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
92.15 USD · Analysts' mean
EPS, year to Dec 2026
-2.93 · 10 analysts
Revenue, year to Dec 2026
4.69M · 12 analysts

Team and board

Officers

OfficerRole
Arthur KuanChairman, President & Chief Executive Officer
Jim DeToreChief Financial Officer
Josh PattersonGeneral Counsel & Chief Compliance Officer
Megan KnightInvestor Relations
Sarah ConnorsVice President, Communications and Patient Advocacy
Brian LiuManaging Director, Longitude Capital
Christina RossiBiopharmaceutical Executive & Board Member
Isabel KalofonosChief Commercial Officer
Jim MuléDirector of Cell-based Therapies, Moffitt Cancer Center
Leonard PostChief Scientific Officer, Vivace Therapeutics
Swapnil BhargavaChief Technical Officer
Victor TongManaging Director, Decheng Capital
Vijay KasturiChief Medical Officer

Board

DirectorRole
Arthur KuanChairman, President & Chief Executive Officer
Christina RossiBiopharmaceutical Executive & Board Member
Leonard PostChief Scientific Officer, Vivace Therapeutics

Events

QuarterResultsShare move
Q3 2026Nov 6, 2026 · Before open+17.3%
Q2 2026Aug 6, 2026 · Before open+3.4%
Q1 2026May 8, 2026 · Before open+0.6%
Q4 2025Mar 27, 2026−4.1%
Q3 2025Nov 14, 2025 · Before open+8.6%
Q2 2025Aug 8, 2025 · Before open+2.0%
Q1 2025May 13, 2025 · Before open−3.9%
Q4 2024Mar 28, 2025−9.1%
Q3 2024Nov 12, 2024 · Before open−6.8%
Q2 2024Aug 8, 2024 · Before open+7.0%
All 12 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open−7.4%
Q4 2023Mar 26, 2024 · Before open+0.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck31 slidesNov 16, 2026
New England Section of the American Urological Association Annual Meeting 2026Conference8 slidesOct 24, 2026
New England Section of the American Urological Association Annual Meeting 2026Conference12 slidesOct 23, 2026
SUO Annual Meeting at AUA 2026Conference15 slidesMay 16, 2026
EAU Annual Meeting (EAU26) 2026Conference8 slidesMar 16, 2026
Investor Presentation (January 2026)Investor deck28 slidesJan 9, 2026
Investor Presentation (2026)Investor deck30 slides2026
SUO Annual Meeting (SUO25) 2025Conference13 slidesDec 5, 2025
EAU 2025Conference7 slidesNovember 2025
Technical Presentation (November 2025)Technical7 slidesNovember 2025
All 31 decks
DeckKindSlidesDate
Technical Presentation (November 2025)Technical7 slidesNovember 2025
NCSAUA 2025Conference12 slidesOct 16, 2025
Technical Presentation (October 2025)Technical14 slidesOct 16, 2025
NCSAUA 2025Conference12 slidesOct 16, 2025
NCSAUA Annual Meeting 2025Conference11 slidesOct 16, 2025
Investor Presentation (September 2025)Investor deck31 slidesSep 9, 2025
Technical Presentation (September 2025)Technical14 slidesSep 6, 2025
ASCO Annual Meeting 2025Conference9 slidesJun 2, 2025
AUA Annual Meeting 2025Conference14 slidesApr 26, 2025
Technical Presentation (April 2025)Technical13 slidesApr 25, 2025
40th Annual EAU Congress (EAU25) (March 2025)Conference14 slidesMar 24, 2025
Technical Presentation (March 2025)Technical12 slidesMar 12, 2025
ASCO Annual Meeting 2024Conference13 slidesJun 2, 2024
Investor Presentation (June 2024)Investor deck28 slidesJune 2024
AUA Annual Meeting 2024Conference16 slidesMay 5, 2024
AUA Annual Meeting 2024Conference17 slidesMay 3, 2024
Investor Presentation (January 2024)Investor deck26 slidesJanuary 2024
Technical Presentation (2024)Technical14 slides2024
ASCO Genitourinary Cancers Symposium 2024Conference8 slides2024
SUO Annual Meeting 2023Conference15 slidesDec 1, 2023
AUA 2023 Annual MeetingConference12 slides2023

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$238M raised · US$28 a share · Morgan Stanley & Co. LLC +4
Dealers: Morgan Stanley & Co. LLC (co-lead), Goldman Sachs & Co. LLC (co-lead), TD Cowen (co-lead), Stifel, Nicolaus & Company, Incorporated (co-lead), LifeSci Capital LLC
Dec 16, 2024

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$19.00 a share on Jan 24, 2024.

Price
US$19.00 a share
Shares offered
20,000,000 shares of common stock
Offering size
US$380 million
Underwriters' option
Up to 3,000,000 more shares
Underwriters
Morgan Stanley, Goldman Sachs & Co. LLC, Cantor, LifeSci Capital · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceOct 27, 2023
Filed publiclyJan 2, 2024
Amended twiceNewest Jan 23, 2024
Shares registered with an exchangeJan 22, 2024
Declared effective by the SECJan 24, 2024
Final prospectus, with the priceJan 25, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Jan 25, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023
Revenue4.04M1.14M204.0K
Research and development116.6M82.1M45.8M
Operating income-190.8M-114.7M-55.4M
Depreciation and amortization1.45M32.0K17.0K
EBITDA-189.3M-114.6M-55.4M
Income tax-270.0K1.00K1.00K
Net income-161.0M-88.0M-48.6M
Earnings per share, basic-2.08-1.41-15.65
Earnings per share, diluted-2.08-1.41-15.65

Balance sheet

LineFY2025FY2024FY2023
Cash and equivalents32.5M257.1M8.27M
Short-term investments709.7M484.9M179.4M
Receivables688.0K0
Inventory1.56M0
Current assets759.5M754.2M194.1M
Property, plant and equipment15.6M272.0K69.0K
Goodwill10.3M0
Total assets791.6M754.8M199.3M
Accounts payable5.71M6.52M3.24M
Current liabilities30.8M21.4M14.3M
Long-term debt3.00M0
Total debt3.00M0
Total liabilities39.0M21.4M14.5M
Shareholders' equity752.6M733.4M-123.1M
Shares outstanding80.7M76.2M5.22M

Cash flow

LineFY2025FY2024FY2023
Cash from operations-132.3M-78.7M-45.7M
Capital spending-134.0K-234.0K
Free cash flow-132.5M-78.9M
Cash from investing-245.8M-300.8M-121.2M
Cash from financing153.6M628.3M87.0M
Change in cash-224.6M248.8M-79.9M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
8-K · Current reportNov 16, 2026Current reportSEC
10-Q · Quarterly reportNov 6, 2026Quarterly reportSEC
8-K · Current reportNov 6, 2026ResultsSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 19, 2026Insider tradeSEC
144 · Notice of proposed saleOct 15, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleSep 21, 2026Other filingsSEC
144 · Notice of proposed saleSep 17, 2026Other filingsSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
144 · Notice of proposed saleSep 2, 2026Other filingsSEC
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
144 · Notice of proposed saleAug 27, 2026Other filingsSEC
144 · Notice of proposed saleAug 25, 2026Other filingsSEC
144 · Notice of proposed saleAug 24, 2026Other filingsSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
144 · Notice of proposed saleAug 14, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 12, 2026Other filingsSEC
144 · Notice of proposed saleAug 11, 2026Other filingsSEC
144 · Notice of proposed saleAug 10, 2026Other filingsSEC
144 · Notice of proposed saleAug 7, 2026Other filingsSEC
144 · Notice of proposed saleAug 6, 2026Other filingsSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
424B5 · ProspectusAug 6, 2026Offer documentSEC
144 · Notice of proposed saleAug 5, 2026Other filingsSEC
144 · Notice of proposed saleJul 29, 2026Other filingsSEC
144 · Notice of proposed saleJul 28, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
144 · Notice of proposed saleJul 27, 2026Other filingsSEC
144 · Notice of proposed saleJul 23, 2026Other filingsSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
4 · Change in ownershipJul 14, 2026Insider tradeSEC
144 · Notice of proposed saleJul 10, 2026Other filingsSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
144 · Notice of proposed saleJun 24, 2026Other filingsSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
8-K · Current reportJun 8, 2026Meeting outcomeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
8-K · Current reportMay 26, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2026Quarterly reportSEC
8-K · Current reportMay 8, 2026ResultsSEC
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
144 · Notice of proposed saleApr 17, 2026Other filingsSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
8-K · Current reportApr 13, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
S-8 · Registration statement for employee plansFeb 27, 2026Offer documentSEC
10-K · Annual reportFeb 27, 2026Annual reportSEC
8-K · Current reportFeb 27, 2026ResultsSEC
8-K · Current reportJan 13, 2026Current reportSEC
424B5 · ProspectusJan 13, 2026Offer documentSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
144 · Notice of proposed saleJan 9, 2026Other filingsSEC
8-K · Current reportJan 9, 2026Current reportSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 26, 2025Insider tradeSEC
8-K · Current reportNov 26, 2025Management or board changeSEC
3 · Initial statement of ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
8-K · Current reportNov 14, 2025Management or board changeSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportNov 14, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 30, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 28, 2025Big-stake noticeSEC
4 · Change in ownershipOct 15, 2025Insider tradeSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
144 · Notice of proposed saleOct 9, 2025Other filingsSEC
4 · Change in ownershipOct 1, 2025Insider tradeSEC
4 · Change in ownershipSep 30, 2025Insider tradeSEC
144 · Notice of proposed saleSep 30, 2025Other filingsSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
SCHEDULE 13D · Big-stake noticeSep 18, 2025Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeSep 18, 2025Big-stake noticeSEC
144 · Notice of proposed saleSep 18, 2025Other filingsSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
144 · Notice of proposed saleSep 15, 2025Other filingsSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
8-K · Current reportSep 9, 2025Current reportSEC
4 · Change in ownershipSep 8, 2025Insider tradeSEC
144 · Notice of proposed saleSep 5, 2025Other filingsSEC
8-K · Current reportSep 5, 2025Current reportSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
144 · Notice of proposed saleSep 3, 2025Other filingsSEC
144 · Notice of proposed saleSep 3, 2025Other filingsSEC
10-Q · Quarterly reportAug 8, 2025Quarterly reportSEC
8-K · Current reportAug 8, 2025ResultsSEC
3 · Initial statement of ownershipAug 6, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2025Big-stake noticeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
144 · Notice of proposed saleJul 17, 2025Other filingsSEC
8-K · Current reportJul 11, 2025Management or board changeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
8-K · Current reportJun 6, 2025Meeting outcomeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
4 · Change in ownershipApr 29, 2025Insider tradeSEC
8-K · Current reportApr 28, 2025Current reportSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
S-3ASR · Registration statementMar 28, 2025Offer documentSEC
10-K · Annual reportMar 28, 2025Annual reportSEC
8-K · Current reportMar 28, 2025ResultsSEC
8-K · Current reportMar 24, 2025Current reportSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
144 · Notice of proposed saleMar 17, 2025Other filingsSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 28, 2025Big-stake noticeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
8-K · Current reportJan 10, 2025Management or board changeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
424B4 · ProspectusDec 13, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 13, 2024Other filingsSEC
S-1/A · Registration statement, amendedDec 11, 2024Offer documentSEC
CORRESP · Letter to the SECDec 11, 2024Other filingsSEC
CORRESP · Letter to the SECDec 11, 2024Other filingsSEC
S-1 · Registration statementDec 11, 2024Offer documentSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
144 · Notice of proposed saleDec 6, 2024Other filingsSEC
8-K · Current reportDec 5, 2024Current reportSEC
UPLOAD · Letter from the SECNov 21, 2024Other filingsSEC
DRS · Draft registration statementNov 14, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
4 · Change in ownershipOct 7, 2024Insider tradeSEC
4 · Change in ownershipOct 7, 2024Insider tradeSEC
4 · Change in ownershipOct 7, 2024Insider tradeSEC
4 · Change in ownershipOct 7, 2024Insider tradeSEC
4 · Change in ownershipOct 7, 2024Insider tradeSEC
4 · Change in ownershipOct 7, 2024Insider tradeSEC
4 · Change in ownershipOct 7, 2024Insider tradeSEC
4 · Change in ownershipOct 7, 2024Insider tradeSEC
4 · Change in ownershipOct 7, 2024Insider tradeSEC
4 · Change in ownershipOct 7, 2024Insider tradeSEC
4 · Change in ownershipAug 30, 2024Insider tradeSEC
144 · Notice of proposed saleAug 29, 2024Other filingsSEC
144 · Notice of proposed saleAug 29, 2024Other filingsSEC
144 · Notice of proposed saleAug 29, 2024Other filingsSEC
144 · Notice of proposed saleAug 29, 2024Other filingsSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
SC 13G · Big-stake noticeJul 22, 2024Big-stake noticeSEC
8-K · Current reportMay 24, 2024Current reportSEC
4 · Change in ownershipMay 16, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 16, 2024Insider tradeSEC

This page holds 200 of 249 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from CG Oncology, Inc.’s releases · as of Nov 4, 2026

Common shares
89,318,916
Fully diluted
89,318,916

Fully diluted

LineSharesAs of
Common shares89,318,916Nov 4, 2026

Share count over time

CountShares
Nov 4, 202689,318,916

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
T. Rowe Price9.83MUS$697MSep 30, 2026
Rtw Investments, LP8.51MUS$604MSep 30, 2026
Vanguard7.75MUS$549MSep 30, 2026
Decheng Capital LLC6.37MUS$452MSep 30, 2026
BlackRock6.35MUS$450MSep 30, 2026
Wellington4.92MUS$349MSep 30, 2026
Fidelity4.59MUS$326MSep 30, 2026
TCG Crossover Management, LLC3.67MUS$260MSep 30, 2026
State Street3.23MUS$229MSep 30, 2026
Geode Capital2.23MUS$158MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Foresite Capital Management VI LLC2.11MUS$150MSep 30, 2026
Seven Fleet Capital Management LP1.89MUS$134MSep 30, 2026
EcoR1 Capital, LLC1.87MUS$133MSep 30, 2026
Franklin Templeton1.64MUS$113MSep 30, 2026
Morgan Stanley1.5MUS$106MSep 30, 2026
UBS1.5MUS$106MSep 30, 2026
DV Trading LLC1.44MUS$102MSep 30, 2026
Avidity Partners Management LP1.35MUS$95.6MSep 30, 2026
Bank of America1.3MUS$92.1MSep 30, 2026
AllianceBernstein1.23MUS$87.2MSep 30, 2026
Goldman Sachs1.14MUS$80.6MSep 30, 2026
Acorn Capital Advisors, LLC1.13MUS$80.2MSep 30, 2026
Foresite Capital Management V, LLC1.08MUS$76.5MSep 30, 2026
TD982KUS$69.5MSep 30, 2026
Logos Global Management LP975KUS$69.1MSep 30, 2026
Hood River Capital Management LLC884KUS$62.7MSep 30, 2026
Jefferies Financial Group Inc.835KUS$59.2MSep 30, 2026
American Century731KUS$51.8MSep 30, 2026
Schwab708KUS$50.2MSep 30, 2026
Northern Trust678KUS$48MSep 30, 2026
BNP Paribas578KUS$41MSep 30, 2026
Bellevue Group AG494KUS$35MSep 30, 2026
Fisher Asset Management, LLC477KUS$33.8MSep 30, 2026
Lord, Abbett & Co. LLC471KUS$33.4MSep 30, 2026
Woodline Partners LP415KUS$29.4MSep 30, 2026
Candriam S.C.A.375KUS$26.7MSep 30, 2026
JPMorgan373KUS$26.5MSep 30, 2026
Eventide Asset Management, LLC370KUS$26.3MSep 30, 2026
Dimensional349KUS$24.8MSep 30, 2026
Federated Hermes, Inc.334KUS$23.7MSep 30, 2026
Ensign Peak Advisors, Inc297KUS$21MSep 30, 2026
First Trust273KUS$19.4MSep 30, 2026
BNY271KUS$19.2MSep 30, 2026
Susquehanna256KUS$18.2MSep 30, 2026
Russell Investments Group, Ltd.249KUS$17.6MSep 30, 2026
Sun Life221KUS$15.6MSep 30, 2026
Ameriprise213KUS$15.1MSep 30, 2026
Pictet Asset Management Holding SA199KUS$14.1MSep 30, 2026
TimesSquare Capital Management, LLC192KUS$13.6MSep 30, 2026
Public Sector Pension Investment Board182KUS$11.4MSep 30, 2026

This page holds 50 of 222 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Health Care Fund2.86MUS$204MJul 31, 2026
T. Rowe Price Capital Appreciation Fund2.57MUS$183MJun 30, 2026
Vanguard Total Stock Market Index Fund2.38MUS$169MJun 30, 2026
iShares Russell 2000 ETF1.89MUS$135MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.81MUS$129MJun 30, 2026
Vanguard Small-Cap Index Fund1.72MUS$122MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.1.11MUS$79.2MJun 30, 2026
Vanguard Extended Market Index Fund860KUS$61.1MJun 30, 2026
Fidelity Small Cap Index Fund807KUS$57.4MJul 31, 2026
Fidelity Small Cap Growth Fund797KUS$56.8MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
T. Rowe Price Mid-Cap Growth Fund, Inc.745KUS$52.9MJun 30, 2026
iShares Russell 2000 Growth ETF681KUS$48.4MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund659KUS$46.8MJun 30, 2026
JNL/T. Rowe Price Capital Appreciation Fund593KUS$42.2MJun 30, 2026
Small Cap Growth Fund554KUS$39.5MJul 31, 2026
Vanguard Small-Cap Value Index Fund545KUS$38.7MJun 30, 2026
Select Health Care Portfolio500KUS$31.1MMay 31, 2026
Vanguard Small-Cap Growth Index Fund496KUS$35.3MJun 30, 2026
Fidelity Small Cap Growth K6 Fund480KUS$34.2MJul 31, 2026
Vanguard Explorer Fund467KUS$33.3MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.438KUS$31.1MJun 30, 2026
iShares Biotechnology ETF407KUS$28.9MJun 30, 2026
Eventide Healthcare & Life Sciences Fund366KUS$26MJun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund364KUS$22.6MMay 31, 2026
AB Small Cap Growth Portfolio356KUS$25.3MJun 30, 2026
Fidelity Extended Market Index Fund354KUS$22.1MMay 31, 2026
Schwab U.S. Small-Cap ETF329KUS$20.5MMay 31, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.305KUS$21.7MJun 30, 2026
Vanguard Russell 2000 Index Fund304KUS$18.9MMay 31, 2026
Lord Abbett Developing Growth Fund Inc299KUS$21.3MJul 31, 2026
AB Discovery Growth Fund, Inc.279KUS$19.8MJun 30, 2026
Vy(R) T. Rowe Price Capital Appreciation Portfolio256KUS$18.2MJun 30, 2026
T. Rowe Price Capital Appreciation Equity ETF248KUS$17.6MJun 30, 2026
Fidelity Advisor Health Care Fund228KUS$16.2MJul 31, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund209KUS$14.9MJul 31, 2026
Putnam Small Cap Growth Fund204KUS$14.5MJun 30, 2026
Franklin Small-Mid Cap Growth Fund200KUS$14.3MJul 31, 2026
Franklin Small Cap Growth Fund193KUS$13.7MJul 31, 2026
ClearBridge Small Cap Growth Fund188KUS$13.4MJul 31, 2026
Penn Series Flexibly Managed Fund182KUS$12.9MJun 30, 2026
Schwab Small-Cap Index Fund179KUS$12.8MJul 31, 2026
Franklin Biotechnology Discovery Fund175KUS$12.4MJul 31, 2026
T. Rowe Price Institutional Small-Cap Stock Fund167KUS$11.8MJun 30, 2026
Fidelity Advisor Biotechnology Fund158KUS$11.2MJul 31, 2026
T. Rowe Price Small-Cap Value Fund, Inc.155KUS$11MJun 30, 2026
Fidelity Small Cap Discovery Fund148KUS$10.5MJul 31, 2026
Master Small Cap Index Series136KUS$9.67MJun 30, 2026
Federated Hermes MDT Small Cap Core Fund133KUS$9.49MJul 31, 2026
EQ/AB Small Cap Growth Portfolio133KUS$9.46MJun 30, 2026
Fidelity Total Market Index Fund129KUS$8.06MMay 31, 2026

This page holds 50 of 326 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Kalofonos Isabel
Officer: Chief Commercial Officer
Buy3,751USD 79.75US$299KNov 18, 2026
Kuan Arthur
Director, Officer: Chief Executive Officer
Buy30,000USD 78.88US$2.37MNov 18, 2026
Post Leonard E
Director
Sale1,000USD 92.00US$92,000Nov 16, 2026
Post Leonard E
Director
Sale500USD 61.65US$30,825Oct 15, 2026
Post Leonard E
Director
Sale500USD 62.48US$31,240Oct 15, 2026
Post Leonard E
Director
Sale1,000USD 72.98US$72,980Sep 15, 2026
Post Leonard E
Director
Sale1,000USD 74.54US$74,540Aug 14, 2026
Post Leonard E
Director
Sale1,000USD 71.17US$71,170Jul 15, 2026
Mulay James
Director
Sale24,165USD 75.16US$1.82MJul 10, 2026
Liu Brian Guan-Chyun
Director
Buy371,085USD 66.87US$24.8MJun 25, 2026
All 16 trades
TradeTradeSharesPriceValueDate
Post Leonard E
Director
Sale5,000USD 70.00US$350KJun 24, 2026
Post Leonard E
Director
Sale5,000USD 65.00US$325KJun 22, 2026
Mulay James
Director
Sale654USD 60.12US$39,318Jun 15, 2026
Mulay James
Director
Sale1,310USD 60.12US$78,757Jun 15, 2026
Post Leonard E
Director
Sale1,000USD 54.50US$54,500Jun 4, 2026
Mulay James
Director
Sale15,600USD 73.01US$1.14MApr 17, 2026

Big stakes

StakeStakeSharesDateFiling
Rtw Investments, LP9.70%8.51MJun 30, 2026Schedule 13G
Xiangmin Cui8.40%6.37MDec 31, 2024Schedule 13G
T. Rowe Price Investment Management, Inc.8.00%6.72MMar 31, 2026Schedule 13G
BlackRock, Inc.6.80%6.02MJun 30, 2026Schedule 13G
Wellington Management Group LLP6.00%5.32MJun 30, 2026Schedule 13G
Patrick G. Enright6.00%4.66MSep 11, 2025Schedule 13D
SONG, Hong Fang5.50%4.21MDec 31, 2024Schedule 13G
FMR LLC5.10%3.86MJun 30, 2025Schedule 13G
Seven Fleet Capital Management LP1.90%1.52MOct 6, 2025Schedule 13D
Seven Fleet Partners LP1.90%1.52MSep 11, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Christina Rossi
Other companies: Xilio Therapeutics, Inc. (Director · Since at least Oct 21, 2021); Blueprint Medicines Corp (Chief Operating Officer · Since at least Oct 29, 2018)
Biopharmaceutical Executive & Board Member · Since at least Nov 24, 2025
Corleen Roche
Other companies: Iovance Biotherapeutics, Inc. (Chief Financial Officer · Since at least Jul 15, 2025); Immunome, Inc. (Chief Financial Officer · Apr 19, 2021 – Jun 8, 2023 · Past)
CFO · Jan 24, 2024 – Apr 15, 2025 · Past
Isabel Kalofonos
Other companies: Crinetics Pharmaceuticals, Inc. (Chief Commercial Officer · Since at least Dec 16, 2024); ImmunoGen Inc (SVP & CHIEF COMMERCIAL OFFICER · Apr 24, 2023 – Feb 12, 2024 · Past)
Chief Commercial Officer · Since at least Nov 18, 2026
James M Detore
Other companies: Kineta Inc. (See Remarks · Aug 4, 2016 – Aug 4, 2016 · Past); Bluebird bio Inc (Chief Financial Officer · Nov 10, 2014 – Dec 1, 2014 · Past)
Chief Financial Officer · Since at least Nov 17, 2025
Josh Patterson
Other companies: Gamida Cell Ltd (GENERAL COUNSEL · Jan 1, 2022 – Jan 31, 2024 · Past); Akcea Therapeutics Inc (General Counsel · Mar 6, 2020 – Oct 12, 2020 · Past)
See Remarks · Since at least May 13, 2024
Susan E. Graf
Other companies: Aardvark Therapeutics, Inc. (Board Member · Since at least Feb 12, 2025); Epizyme Inc (Chief Business Officer · Apr 25, 2016 – Feb 9, 2018 · Past)
Director · Since at least Jan 24, 2024
James Mulay
Other companies: Fulgent Genetics, Inc. (Director · May 30, 2019 – May 30, 2019 · Past)
Director · Since at least Jan 24, 2024
John McAdory
Other companies: Oncolytics Biotech Inc. (Chief Operating Officer · Since at least Jun 2, 2026)
EVP of Strategy and Operations · Jan 14, 2026 – Nov 5, 2026 · Past
Victor Tong
Other companies: Aardvark Therapeutics, Inc. (Managing Director · Since at least Nov 5, 2026)
Managing Director, Decheng Capital · Since at least Nov 5, 2026
Ambaw BelletePresident and COO · Since at least Apr 15, 2025
All 21 people
PersonSeat
Arthur KuanChairman, President & Chief Executive Officer · Since at least Jan 24, 2024
Brian LiuManaging Director, Longitude Capital · Since at least Jan 24, 2024
Hong Fang SongDirector · Since at least Jan 24, 2024
Isabel KalofonosChief Commercial Officer · Since at least Oct 13, 2026
Jim DeToreChief Financial Officer · Since at least Nov 5, 2026
Jim MuléDirector of Cell-based Therapies, Moffitt Cancer Center · Since at least Nov 5, 2026
Leonard PostChief Scientific Officer, Vivace Therapeutics · Since at least Oct 19, 2026
Megan KnightInvestor Relations · Since at least Sep 2, 2026
Sarah ConnorsVice President, Communications and Patient Advocacy · Since at least Sep 2, 2026
Swapnil BhargavaChief Technical Officer · Since at least Nov 5, 2026
Vijay KasturiChief Medical Officer · Since at least Jan 24, 2024

Open People

Log in to ask 6ix AI your own questions about CG Oncology, Inc.